Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells

IUBMB Life

Volumn 65, Issue 8, 2013, Pages 716-729

  Tolba, Mai F ^a   Esmat, Ahmed ^a   Al Abd, Ahmed M ^c   Azab, Samar S ^a   Khalifa, Amani E ^a   Mosli, Hisham A ^e   Abdel Rahman, Sherif Z ^b   Abdel Naim, Ashraf B ^a,d  

^a African Union Organization St Abbassia   (Egypt)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e King Abdulaziz University   (Saudi Arabia)

Author keywords

caffeic acid phenethyl ester; estrogen receptors; prostate cancer; taxanes

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; CASPASE 3; CYCLIN D1; DOCETAXEL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; ONCOGENE C MYC; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

EID: 84890624288     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1188     Document Type: Article

References (46)

1. Bankova, V., Dyulgerov, A., Popov, S., and, Marekov, N., (1987) A GC/MS study of the propolis phenolic constituents. Z. Naturforsch. 42, 147-151.
2. Lee, K. W., Kang, N. J., Kim, J. H., Lee, K. M., Lee, D. E., et al. (2008) Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B. Genes Nutr. 2, 319-22. (Pubitemid 351447705)
3. Wu, J., Omene, C., Karkoszka, J., Bosland, M., Eckard, J., et al. (2011) Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. Cancer Lett. 308, 43-53.
4. Chuu, C. P., Lin, H. P., Ciaccio, M. F., Kokontis, J. M., Hause, R. J., Jr,., et al., (2012) Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks. Cancer Prev. Res. 5, 788-797.
5. Grunberger, D., Banerjee, R., Eisinger, K., Oltz, E. M., Efros, L., et al. (1988) Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 44, 230-232. (Pubitemid 18066629)
6. Su, Z. Z., Lin, J., Prewett, M., Goldstein, N. I., and, Fisher, P. B., (1995) Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryofibroblast cells. Anticancer Res. 15, 1841-1848. (Pubitemid 26032268)
7. Akyol, S., Ginis, Z., Armutcu, F., Ozturk, G., Yigitoglu, M. R., et al. (2012) The potential usage of caffeic acid phenethyl ester (CAPE) against chemotherapy-induced and radiotherapy-induced toxicity. Cell Biochem. Funct. 30, 438-443.
8. Sugar, L. M., (2006) Inflammation and prostate cancer. Can J Urol. 13, 46-47.
9. Battisti, V., Maders, L. D., Bagatini, M. D., Reetz, L. G., Chiesa, J., et al., (2011) Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomed. Pharmacother. 65, 516-524.
10. McEleny, K., Coffey, R., Morrissey, C., Fitzpatrick, J. M., and, Watson, R. W., (2004) Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins. BJU Int. 94, 402-406. (Pubitemid 39120188)
11. Jung, B. I., Kim, M. S., Kim, H. A., Kim, D., Yang, J., et al. (2010) Caffeic acid phenethyl ester, a component of beehive propolis, is a novel selective estrogen receptor modulator. Phytother. Res. 24, 295-300.
12. Jemal, A., Siegel, R., Xu, J., and, Ward, E., (2010) Cancer statistics. CA Cancer J. Clin. 60, 277-300.
13. Pinto, A. C., Moreira, J. N., and, Simões, S., (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a scheduledependent manner. Cancer Chemother. Pharmacol. 64, 445-454.
14. Diaz, M., and, Patterson, S. G., (2004) Management of androgen-independent prostate cancer. Cancer Control. 11, 364-373. (Pubitemid 39602210)
15. Bonkhoff, H., Fixemer, T., Hunsicker, I., and, Remberger, K., (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. 155, 641-647. (Pubitemid 29370414)
16. Sissung, T. M., Danesi, R., Price, D. K., Steinberg, S. M., de Wit, R., et al. (2008) Association of the CYP1B13 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 1, 19-26.
17. Celhay, O., Yacoub, M., Irani, J., Dore, B., Cussenot, O., et al. (2010) Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J. Urol. 184, 2172-2178.
18. Ellem, S. J., and, Risbridger, G. P., (2009) The dual, opposing roles of estrogen in the prostate. Ann. N Y Acad. Sci. 1155, 174-186.
19. Kurahashi, N., Iwasaki, M., Sasazuki, S., Otani, T., Inoue, M., et al. (2007) Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol. Biomarkers Prev. 16, 538-545. (Pubitemid 46548658)
20. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112. (Pubitemid 20213250)
21. Chou, T. C., and, Talalay, P., (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55.
22. Blesa, J. M., and, Candel, V. A., (2010) PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient. Onkologie 33, 57-59.
23. Shazer, R. L., Jain, A., Galkin, A. V., Cinman, N., Nguyen, K. N., et al. (2006) Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 97, 691-697. (Pubitemid 43383496)
24. Obasaju, C., and, Hudes, G. R., (2001) Paclitaxel and docetaxel in prostate cancer. Hematol. Oncol. Clin. North Am. 15, 525-545. (Pubitemid 32762172)
25. Umekita, Y., Hiipakka, R. A., Kokontis, J. M., and, Liao, S., (1996) prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Hum. Proc. Natl. Acad. Sci. USA 93, 11802-11807. (Pubitemid 26347204)
26. Lin, H. P., Jiang, S. S., and, Chuu, C. P., (2012) Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS One 7, e31286.
27. Haldar, S., Basu, A., and, Croce, C. M., (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res. 57, 229-233. (Pubitemid 27038278)
28. Stein, C. A., (1999) Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 5, 3-7. (Pubitemid 30000737)
29. Nupponen, N. N., Kakkola, L., Koivisto, P., and, Visakorpi, T., (1998) Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 153, 141-148. (Pubitemid 28317516)
30. Bernard, D., Pourtier-Manzanedo, A., Gil, J., and, Beach, D. H., (2003) Myc confers androgen-independent prostate cancer cell growth. J. Clin. Invest. 112, 1724-1731. (Pubitemid 38063730)
31. Mackey, T. J., Borkowski, A., Amin, P., Jacobs, S. C., and, Kyprianou, N., (1998) Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52, 1085-1090. (Pubitemid 28533381)
32. Apakama, I., Robinson, M. C., Walter, N. M., Charlton, R. G., Royds, J. A., et al. (1996) Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br. J. Cancer 74, 1258-1262. (Pubitemid 26360116)
33. Jin, U. H., Song, K. H., Motomura, M., Suzuki, I., Gu, Y. H., et al. (2008) Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells. Mol. Cell. Biochem. 310, 43-48.
34. Haldar, S., Chintapalli, J., and, Croce, C. M., (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56, 1253-1255. (Pubitemid 26080965)
35. Gu, C., Casaccia-Bonnefil, P., Srinivasan, A., and, Chao, M. V., (1999) Oligodendrocyte apoptosis mediated by caspase activation. J. Neurosci. 19, 3043-3049. (Pubitemid 29174000)
36. Cheng, J., Lee, E. J., Madison, L. D., and, Lazennec, G., (2004) Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 566, 169-172. (Pubitemid 38625953)
37. Choi, K. C., Kang, S. K., Tai, C. J., Auersperg, N., and, Leung, P. C., (2001) Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142, 2351-2360. (Pubitemid 32473090)
38. Nakajima, Y., Akaogi, K., Suzuki, T., Osakabe, A., Yamaguchi, C., et al. (2011) Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5. Sci. Signal. 4, ra22.
39. Medema, R. H., Kops, G. J., Bos, J. L., and, Burgering, B. M., (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782-787. (Pubitemid 30212408)
40. Ricke, W. A., McPherson, S. J., Bianco, J. J., Cunha, G. R., Wang, Y., et al. (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 22, 1512-1520. (Pubitemid 351656791)
41. Zhou, D., Li, S., Wang, X., Cheng, B., and, Ding, X., (2011) Estrogen receptor alpha is essential for the proliferation of prostatic smooth muscle cells stimulated by 17β-estradiol and insulin-like growth factor 1. Cell Biochem Funct. 29, 120-125.
42. Fagan, D. H., and, Yee, D., (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia. 13, 423-429.
43. Mulholland, D. J., Dedhar, S., Wu, H., Nelson, C. C., (2006) PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25, 329-337. (Pubitemid 43117618)
44. Yager, J. D., and, Davidson, N. E., (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282.
45. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824.
46. Liu, M. M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., et al. (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 277, 24353-24360. (Pubitemid 34951956)